Dupilumab (Atopic Dermatitis)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 9
2.3 Upcoming Related Reports 10
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 12
3.2 Symptoms 16
4 Disease Management 18
4.1 Diagnosis 18
4.2 Treatment Overview 20
5 Competitive Assessment 26
5.1 Overview 26
5.2 Strategic Competitor Assessment 27
6 Opportunity and Unmet Need 29
6.1 Overview 29
6.2 Unmet Needs 30
6.2.1 A Systemic Drug for Severe Recalcitrant Patients 30
6.2.2 Tests that Stratify Patients and Allow for a Tailored Treatment Approach 32
6.2.3 A Drug that Effectively Controls Patients’ Pruritus 33
6.2.4 Further Research into the Pathophysiology of Atopic Dermatitis 34
6.2.5 A Drug that Induces Disease Remission 35
6.2.6 Improved Quality of Life for Both Patients and their Carers 36
6.3 Unmet Needs Gap Analysis 36
6.4 Opportunities 38
6.4.1 Increase Treatment Armamentarium for Severe Recalcitrant Patients 38
6.4.2 Predictive Tests for Patient Stratification 38
6.4.3 More Therapeutic Options that Address Patients’ Pruritus 39
7 Pipeline Assessment 40
7.1 Overview 40
7.2 Promising Drugs in Clinical Development 42
8 Dupilumab (SAR231893/ REGN668) 44
8.1 Overview 44
8.2 Efficacy 46
8.3 Safety 48
8.4 Dosing and Formulation 48
8.5 Potential Clinical Positioning 49
8.6 Potential Commercial Positioning 51
8.7 Pricing and Reimbursement 51
8.8 SWOT Analysis 53
8.9 Forecast 53
9 Appendix 55
9.1 Bibliography 55
9.2 Abbreviations 57
9.3 Methodology 59
9.4 Forecasting Methodology 59
9.4.1 Diagnosed Atopic Dermatitis Patients 60
9.4.2 Percent Drug-treated Patients 60
9.4.3 General Pricing Assumptions 61
9.4.4 Generic Erosion 62
9.4.5 Pricing of Pipeline Agents 62
9.5 Physicians and Specialists Included in this Study 63
9.6 Primary Research – Prescriber Survey 64
9.7 About the Authors 65
9.7.1 Author 65
9.7.2 Global Head of Healthcare 66
9.8 About GlobalData 67
9.9 Disclaimer 67